MicroPort CardioFlow Medtech Corp. (HK:2160) has released an update.
MicroPort CardioFlow Medtech Corp. has projected a significant reduction in net loss for the first half of 2024, estimating a decrease of 63% to 72% compared to the previous year. This improvement is attributed to increased revenue from product sales, particularly its TAVI products, economies of scale, and enhanced operational efficiency. The company aims to reach break-even by 2025, with final interim results to be released in August 2024.
For further insights into HK:2160 stock, check out TipRanks’ Stock Analysis page.
